Table 2

Comparison of cell surface marker expression by CD14⁺ monocytes

Control individuals

SLE patients without LN

SLE patients with LN

CD14⁺ cells

Percentage^a

4.3 ± 0.4

3.9 ± 0.3

4.0 ± 0.2

Mean fluorescence intensity

596.8 ± 42.9

604.8 ± 29.9

605.3 ± 18.7

Absolute number (cell/μl)

357.2 ± 31.5

254.1 ± 38.5*

268.3 ± 29.4*

FcγRIII/CD16

Percentage^a

9.3 ± 0.7

11.0 ± 0.6*

10.8 ± 0.6

Mean fluorescence intensity

10.2 ± 0.6

13.2 ± 0.6**

12.5 ± 0.4*

Absolute number (cell/μl)

23.3 ± 4.1

53.6 ± 10.0

78.9 ± 15.7

FcγRII/CD32

Percentage^a

87.5 ± 2.9

85.9 ± 2.3

81.8 ± 2.9

Mean fluorescence intensity

71.6 ± 8.3

64.4 ± 7.5

68.4 ± 5.9

Absolute number (cell/μl)

266.7 ± 49.2

249.1 ± 114.5

238.2 ± 100.9

FcγRI/CD64

Percentage^a

99.9 ± 0.03

99.9 ± 0.02

99.9 ± 0.03

Mean fluorescence intensity

319.1 ± 22.2

449.2 ± 30.5**

567.0 ± 28.1**^††

Absolute number (cell/μl)

352.8 ± 0.11

252.8 ± 0.05*

268.0 ± 0.08*

*P < 0.05 or **P < 0.001 for systemic lupus erythematosus (SLE) patients with or without lupus nephritis (LN) versus healthy control individuals. ^†P < 0.05 or ^††P < 0.001 for SLE patients with LN versus SLE patients without LN.

Li et al. Arthritis Research & Therapy 2009 11:R6   doi:10.1186/ar2590